Abstract
Background Opportunistic resistant bacteria are health and economically relevant in the health care systems and in industries worldwide, especially in the so-called resistant bacteria era (RBE). Enhancing the activity of commercially available antibiotics (CAAs) with different types of natural products (NPs) is a successful antimicrobial strategy, for instance the amoxicillin and clavulanate mixture.
Objective To find research trends in this field during 2015-2020 and to detect potential drug hits with potential to diversify formulations and materials design that can be useful to manage the RBE.
Systematic review results It yielded 190 reports of synergistic effects of CAAs and NPs. The analyzed variables were: a) natural products origin: plant family, genera, secondary metabolite type; b) strains: +/- Gram, genera, most frequent species, application field; and c) CAAs: family, most frequent CAAs. The families with potential to have more bioactive species were Apocynaceae, Rubiaceae, Euphorbiaceae (Isbio factor). Lonicera had the highest reports amount.
Polyphenols and flavonoids were the majority of pure NPs tested. Several potential drug hits for antibiotic activity enhancement at synergistic level were identified together with potential mechanisms of action: berberine (drug efflux inhibitor–DEI, biofilm inhibitor–BI), curcumin (BI), essential oils (BI), 3-o-metyl-butylgallato (inhibition of fatty acid saturation), among others. About the half of the tested strains were gram positive, being Methicillin Resistant Staphylococcus aureus (MRSA) the most frequently tested. Escherichia coli was the gram negative strain most frequently reported, including enterotoxigenic and extended spectrum beta-lactamases producers. The growth of other foodborne genera strains, such as Listeria and Salmonella, were also inhibited. Aminoglycosides were the family most reported, with gentamicin as the most commonly studied.
Conclusions NPs as either as plant extracts from a variety of families, or as purified compounds specially flavonoids and polyphenols, have shown effective results to enhance the antibiotic activity of CAAs against gram positive and negative strains relevant to HC and FI. Their mechanisms of action are starting to be determined, as the case EPIs and BIs. Further research is needed to achieve co-formulations and materials design useful for those fields, that can certainly be positively impacted by pursuing this strategy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Data Availability
All data produced in the present study are available upon reasonable request to the authors
